| |
| |
|
| Insider
Information: |
Simon Nicholas J III |
| Relationship: |
Director, 10% Owner |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
149,765 |
|
|
Indirect Shares
|
22,707,997 |
|
|
| Direct
Value |
$7 |
|
|
|
Indirect Value
|
$50,845,030 |
|
|
| Total
Shares |
22,857,762 |
|
|
| Total
Value |
$50,845,037 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Rigel Pharmaceuticals Inc |
RIGL |
Director |
2004-09-17 |
0 |
2004-11-23 |
0 |
Premium* |
|
|
Genitope Corp |
GTOP |
Director |
2003-11-04 |
73,074 |
|
0 |
Premium* |
|
|
Somaxon Pharmaceuticals, Inc. |
SOMX |
10% Owner |
2005-12-20 |
0 |
2009-07-08 |
4,632,562 |
Premium* |
|
|
Poniard Pharmaceuticals |
PARD |
Director, 10% Owner |
2010-06-09 |
72,289 |
2010-06-09 |
6,363,249 |
Premium* |
|
|
Altimmune, Inc |
ALT |
10% Owner |
2007-08-03 |
0 |
2010-11-03 |
6,347,614 |
Premium* |
|
|
Aryx Therapeutics Inc |
ARYX |
Director, 10% Owner |
2007-11-13 |
4,402 |
2008-11-14 |
5,364,572 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
62 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALT |
Altimmune, Inc |
10% Owner |
– – • |
2007-08-03 |
4/A |
A |
$0.00 |
$0 |
I/I |
3,239,443 |
3,364,443 |
0 |
- |
|
| ALT |
Altimmune, Inc |
|
– – – |
2007-08-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
125,000 |
|
- |
|
| ALT |
Altimmune, Inc |
10% Owner |
– – • |
2007-08-03 |
4 |
A |
$0.00 |
$0 |
I/I |
3,218,250 |
3,343,250 |
0 |
- |
|
| ALT |
Altimmune, Inc |
10% Owner |
– – • |
2007-08-07 |
4 |
B |
$7.70 |
$962,500 |
I/I |
125,000 |
3,468,250 |
1.5 |
- |
|
| ALT |
Altimmune, Inc |
10% Owner |
– – • |
2007-08-07 |
4/A |
B |
$7.70 |
$962,500 |
I/I |
125,000 |
3,489,443 |
1.5 |
- |
|
| ALT |
Altimmune, Inc |
10% Owner |
– – • |
2010-11-03 |
4 |
B |
$3.50 |
$1,505,000 |
I/I |
430,000 |
6,347,614 |
1.5 |
- |
|
| ALT |
Altimmune, Inc |
10% Owner |
– – • |
2010-11-03 |
4 |
OE |
$2.54 |
$6,171,682 |
I/I |
2,428,171 |
5,917,614 |
0 |
- |
|
| ARYX |
Aryx Therapeutics Inc |
Director |
– • • |
2007-11-13 |
4 |
B |
$10.00 |
$3,000,000 |
I/I |
300,000 |
3,576,862 |
2.25 |
- |
|
| ARYX |
Aryx Therapeutics Inc |
Director |
– • • |
2007-11-13 |
4 |
A |
$0.00 |
$0 |
I/I |
3,276,862 |
3,276,862 |
0 |
- |
|
| ARYX |
Aryx Therapeutics Inc |
Director |
– • • |
2007-11-13 |
4 |
A |
$0.00 |
$0 |
D/D |
4,402 |
4,402 |
0 |
- |
|
| ARYX |
Aryx Therapeutics Inc |
Director |
– • • |
2008-11-14 |
4 |
B |
$2.20 |
$3,932,962 |
I/I |
1,787,710 |
5,364,572 |
2.25 |
- |
|
| GTOP |
Genitope Corp |
Director |
– • – |
2003-10-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
33,332 |
|
- |
|
| GTOP |
Genitope Corp |
Director |
– • – |
2003-11-04 |
4 |
A |
$0.00 |
$0 |
D/D |
6,410 |
39,742 |
|
- |
|
| PARD |
Poniard Pharmaceuticals |
Director |
– • • |
2006-04-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
35,749,286 |
|
- |
|
| PARD |
Poniard Pharmaceuticals |
Director |
– • • |
2007-04-30 |
4 |
B |
$6.33 |
$5,697,000 |
I/I |
900,000 |
6,858,211 |
2.25 |
- |
|
| PARD |
Poniard Pharmaceuticals |
Director |
– • • |
2009-11-05 |
4 |
S |
$8.00 |
$626,292 |
I/I |
(78,262) |
6,779,949 |
0 |
- |
|
| PARD |
Poniard Pharmaceuticals |
Director |
– • • |
2009-11-06 |
4 |
S |
$8.06 |
$2,132,560 |
I/I |
(264,648) |
6,515,301 |
0 |
- |
|
| PARD |
Poniard Pharmaceuticals |
Director |
– • • |
2009-11-09 |
4 |
S |
$8.50 |
$1,292,442 |
I/I |
(152,052) |
6,363,249 |
0 |
- |
|
| PARD |
Poniard Pharmaceuticals |
Director |
– • • |
2010-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
72,289 |
72,289 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • • |
2003-06-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,340,278 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • • |
2004-02-19 |
4 |
S |
$20.00 |
$3,447,460 |
I/I |
(172,373) |
4,167,905 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • • |
2004-03-19 |
4 |
S |
$20.00 |
$346,680 |
I/I |
(17,334) |
4,150,571 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • • |
2004-04-08 |
4 |
S |
$19.93 |
$6,295,927 |
I/I |
(315,902) |
3,834,669 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • • |
2004-04-12 |
4 |
S |
$19.80 |
$7,920 |
I/I |
(400) |
3,834,269 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • • |
2004-04-19 |
4 |
S |
$20.30 |
$507,500 |
I/I |
(25,000) |
3,809,269 |
|
- |
|
62 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
